ARV regimens in the cohort
| ARV regimen | Overall | Treatment-experienced patients | Naïve patients |
| DTG+ABC/3TC | 1718 (41.5) | 1529 (41.8) | 189 (39.3) |
| DTG+FTC/Tenofovir (either TDF or TAF) | 863 (20.9) | 618 (16.9) | 245 (50.9) |
| DTG+3TC | 616 (14.9) | 608 (16.6) | 8 (1.7) |
| DTG+RPV | 263 (6.4) | 259 (7.1) | 4 (0.8) |
| DTG+PI (boosted or unboosted) | 380 (9.2) | 370 (10.1) | 10 (2.1) |
| DTG monotherapy | 8 (0.2) | 8 (0.2) | 0 |
| Other DTG-based dual regimen | 22 (0.5) | 19 (0.5) | 3 (0.6) |
| Other DTG-based regimen (three or more drugs) | 269 (6.5) | 247 (6.8) | 22 (4.6) |
ARV, antiretroviral; DTG, dolutegravir; PI, protease inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide ; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.